Abstract: The invention provides diagnostic markers of immunosenescence and methods of identifying individuals with impaired immune function based on the expression level of a combination of such markers in a biological sample obtained from said individual. Such combination of markers is useful for determining the susceptibility to nosocomial infections of an individual. Such combination of markers is also useful for predicting whether an individual will respond to active vaccination and become protected against recurring diseases.

Abstract: The invention relates to a compound of the formula Li7?xPS6?xXx?x(BH4)x in which x is selected from the group comprising Cl, Br, I, F and CN, 0?x?2, 0?z?0.50. This compound can be used as a solid electrolyte of a lithium-ion electrochemical element.

Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

Abstract: The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.

Abstract: The present invention relates to highly efficient Nrf2 activators-CO-releasing molecules of formula (I) and (II) capable of increasing HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases, wherein CORM represents a carbonyl metal complex chosen from among: Mn(CO)5, formula (III), (IV), (V), (VI), (VII), (VIII) and (IX).

Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.

Abstract: A stimulation device for activating at least one muscle involved in raising the foot while an individual is walking, comprising sensors which are to be placed on a lower limb of the individual, permitting calculation of a flexion angle of the knee; electrodes which are to be placed on the one or more muscles to be activated and able to electrically stimulate the one or more muscles, and a processing unit with computing means for calculating the value of the flexion angle of the knee on the basis of the measurement signals and for determining the oscillation phase in a walking cycle of the individual, and control means for the electrodes, the control means being designed to activate the electrodes only in the oscillation phase of a walking cycle of the individual, such that the electrodes generate an electrical stimulation with an intensity depending on the flexion angle of the knee, the intensity increasing as the flexion angle of the knee decreases, during the re-extension of the knee during the oscillation

Abstract: Methods for the diagnosis and prognosis of neurodegenerative diseases, such as Alzheimer's disease, are described. Compositions and method for the treatment of neurodegenerative diseases are also described.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1.

Abstract: The present invention relates to a method of prognosis and/or diagnosis of Alzheimer's disease by determining the level and/or cellular distribution of heparan sulfates (HS) and/or heparan sulfate sulfotransferases (HSSTs) from isolating circulating immune cells in said circulating immune cells.

Abstract: The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.

Abstract: The invention relates to a method for fighting fungus-growing ants, and to a formicide composition capable of destroying specifically the colonies of fungus-growing ants. The invention also relates a kit for use with said method.

Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.

Abstract: The invention relates to a material comprising: a first crosslinked polymer forming a network, and a second linear polymer comprising n monomers, each of the monomers having the following formula I: (I), where m varies from 0 to 4, R is selected from hydrogen, an ethyl group and an alkyl group, and n is a non-zero natural integer, said material being such that it forms a semi-interpenetrating network wherein the second linear polymer is entangled in the network of the first polymer.

Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.

Abstract: The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.

Abstract: The invention concerns the use of pyridinium furosemide or one of the derivatives, analogs, salts, metabolites, or prodrugs thereof in the preparation of a chemical model of a neurodegenerative disease, preferably Parkinson's disease. The invention also concerns the corresponding chemical model and the uses of same, in particular in screening tests for identifying drug candidates.

Abstract: The present invention relates methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (GVHD) using populations or compositions of immunoregulatory T cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.

Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.

Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.